Drugs that contain Bupivacaine
1. Exparel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6132766 | PACIRA PHARMS INC | Multivesicular liposomes with controlled release of encapsulated biologically active substances |
Nov, 2013
(10 years ago) | |
| US8182835 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
| US8834921 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
| US9205052 | PACIRA PHARMS INC | Sustained-release liposomal anesthetic compositions |
Sep, 2018
(5 years ago) | |
| US9585838 | PACIRA PHARMS INC | Production of multivesicular liposomes |
Dec, 2021
(2 years ago) | |
| US11452691 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11426348 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11357727 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11819575 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11311486 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11278494 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11304904 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11819574 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
| New Indication(I-771) | Apr 06, 2021 |
| New Product(NP) | Oct 28, 2014 |
Market Authorisation Date: 28 October, 2011
Treatment: Single dose administration into the surgical site to produce postsurgical analgesia; Single-dose infiltration into the surgical site to produce postsurgical analgesia.; Method of treating pain, for ex...
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
EXPAREL family patents
2. Posimir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8153149 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US8753665 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US8846072 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US8153661 | INNOCOLL | Controlled delivery system |
Sep, 2025
(1 year, 4 months from now) | |
| US11400019 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(16 years from now) | |
| US11771624 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 01, 2024 |
Market Authorisation Date: 01 February, 2021
Treatment: Method for providing sustained local anesthesia for at least 24 hours; To produce post-surgical analgesia
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR family patents